An observational Phase 4 APeX-T study, designed to generate real-world data to inform physicians on the best individual approaches to support transition to ORLADEYO
Latest Information Update: 10 Nov 2024
Price :
$35 *
At a glance
- Drugs Berotralstat (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms APeX-T
- Sponsors BioCryst Pharmaceuticals
- 10 Nov 2024 New trial record